Four-Week Data Comparing GI-5005 Plus Standard of Care vs. Standard of Care to be Presented Next Week in Late-Breaking Poster at AASLD Meeting AASLD President Will Highlight Data at President’s Press Conference LOUISVILLE, Colo., Nov. 1, 2008 – Four-week Phase … Continue reading
GlobeImmune Hepatitis C Therapeutic Vaccine, GI-5005, Doubles Viral Clearance and Increases RVR Rates in Phase 2 Clinical Trial
November 01, 2008